Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
Nixon A, Navarro F, Zhou K, Abbott C, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Chen R, Strickler J, Boyle S, Uronis H. Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer. Journal Of Clinical Oncology 2024, 42: 4025-4025. DOI: 10.1200/jco.2024.42.16_suppl.4025.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerMolecular residual diseaseImmune checkpoint blockadeProgression-free survivalCtDNA dynamicsCtDNA levelsHigher hazard ratioOverall survivalDetection of molecular residual diseasePhase II study of pembrolizumabSingle-arm phase II studyWhole-genome sequencingSingle nucleotide variantsMolecular progressionResponse rateStudy of pembrolizumabBaseline prior to treatmentUnivariate Cox regression analysisCox regression analysisFFPE tumor samplesOverall response rateMedian lead timeImprove treatment decision-makingLong-term survivalLiquid biopsy platform
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply